Bottom line
FBT vs PBE: the short answer
FBT (First Trust NYSE Arca Biotechnology Index Fund) and PBE (Invesco Biotechnology & Genome ETF) share a meaningful slice of their top holdings — about 43% by weight.
FBT is cheaper at 0.55% vs 0.59% — a difference of $4.00 a year per $10,000 invested.
Over five years, FBT returned +4.3% a year vs +3.4% for PBE.
Updated Nov 19, 2026
FBT vs PBE side by side
| FBT | PBE | |
|---|---|---|
| Type | ETF | ETF |
| Fund family | First Trust | Invesco |
| Category | Technology Sector | Technology Sector |
| Expense ratio | 0.55% | 0.59% |
| Annual cost per $10k | $55 | $59 |
| 10-yr cost on $10k (prospectus) | — | $738 |
| Max front load | None | None |
| 12b-1 fee | 0% | — |
| 1-yr return | +24.1% | +24.7% |
| 5-yr return (annualized) | +4.3% | +3.4% |
| 10-yr return (annualized) | +6.3% | +5.2% |
| Best quarter | +27.8% | +25.3% |
| Worst quarter | −22.5% | −24.3% |
| Net assets (fund) | $2.8B | $281.9M |
| Number of holdings | 32 | 33 |
| Portfolio turnover | 37% | 103% |
| Returns as of | Dec 31, 2025 | Dec 31, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | FBT | PBE | Difference |
|---|---|---|---|
| 2025 | +24.1% | +24.7% | −0.6% |
| 2024 | +5.8% | +1.1% | +4.7% |
| 2023 | +2.3% | +3.7% | −1.4% |
| 2022 | −4.6% | −10.8% | +6.2% |
| 2021 | −3.6% | +1.6% | −5.2% |
| 2020 | +12.9% | +25.5% | −12.6% |
| 2019 | +19.8% | +18.3% | +1.5% |
| 2018 | −0.2% | +0.2% | −0.4% |
| 2017 | +37.0% | +22.4% | +14.6% |
| 2016 | −19.6% | −23.0% | +3.4% |
Source: Fund prospectus bar charts
Holdings overlap
14 of FBT's top 25 holdings also appear in PBE's top 25.
| Holding | FBT | PBE |
|---|---|---|
| Veracyte Inc | 5.10% | 2.60% |
| Illumina Inc | 3.92% | 3.51% |
| Neurocrine Biosciences Inc | 3.53% | 2.66% |
| Bio-techne Corp | 3.43% | 3.73% |
| Biogen Inc | 3.37% | 4.79% |
| Exelixis Inc | 3.32% | 2.64% |
| Incyte Corp | 3.18% | 3.06% |
| Halozyme Therapeutics Inc | 3.11% | 2.98% |
| Vertex Pharmaceuticals Inc | 3.07% | 4.99% |
| Repligen Corp | 3.07% | 3.04% |
| Biomarin Pharmaceutical Inc | 2.83% | 2.82% |
| Amgen Inc | 2.78% | 5.22% |
| United Therapeutics Corp | 2.56% | 4.08% |
| Alnylam Pharmaceuticals Inc | 2.52% | 3.17% |
Source: SEC Form N-PORT
FBT top 10
- Corcept Therapeutics Inc — 5.60%
- Neogenomics Inc — 5.12%
- Veracyte Inc — 5.10%
- Bruker Corp — 4.32%
- Alkermes Plc — 4.24%
- Illumina Inc — 3.92%
- Krystal Biotech Inc — 3.87%
- Natera Inc — 3.79%
- Axsome Therapeutics Inc — 3.71%
- Neurocrine Biosciences Inc — 3.53%
PBE top 10
- Invesco Private Prime Fund — 12.89%
- Regeneron Pharmaceuticals, Inc. — 5.47%
- Amgen Inc. — 5.22%
- CareDx, Inc. — 5.04%
- Vertex Pharmaceuticals Inc. — 4.99%
- Invesco Private Government Fund — 4.97%
- Royalty Pharma PLC — 4.94%
- Biogen Inc. — 4.79%
- Gilead Sciences, Inc. — 4.43%
- United Therapeutics Corp. — 4.08%
FAQ
What is the difference between FBT and PBE?
Which is cheaper, FBT or PBE?
Should I own both FBT and PBE?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.